Windlas BiotechNSE:WINDLAS -0.56%86 Current Ratio is 1.95 as of Mar. 2026, which is 7% below its 10-year median of 2.10. GuruFocus rates NSE:WINDLAS with a GF Score™ of 86/100 and a GF Value™ of ₹936.98 (Fairly Valued). The stock has 1 warning sign investors should review. Among 995 Drug Manufacturers companies, Windlas Biotech ranks worse than 51.16% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Windlas Biotech's current ratio for the quarter that ended in Mar. 2026 was 1.95.
Windlas Biotech has a current ratio of 1.95. It generally indicates good short-term financial strength.
The historical rank and industry rank for Windlas Biotech's Current Ratio or its related term are showing as below:
NSE:WINDLAS'
s Current Ratio Range Over the Past 10 Years
Min: 1.25 Med: 2.1 Max: 4.06
Current: 1.95
During the past 8 years, Windlas Biotech's highest Current Ratio was 4.06. The lowest was 1.25. And the median was 2.10.
NSE:WINDLAS's Current Ratio is ranked worse than 51.16% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:WINDLAS: 1.95
Windlas Biotech (NSE:WINDLAS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Windlas Biotech Current Ratio Related Terms
Windlas Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WINDLAS vs ZTS, UTHR: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a Current Ratio of 1.95 as of Mar. 2026. This is near median its historical median of 2.10. Over the past decade, Windlas Biotech's Current Ratio has ranged from 1.25 to 4.06. According to the industry distribution chart, Windlas Biotech ranks #509 out of 995 companies in the Drug Manufacturers industry, placing it in the top 51.2%.
Is Windlas Biotech's Current Ratio too high?
Windlas Biotech's current Current Ratio of 1.95 is near median its 10-year median of 2.10. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 4.06. The Drug Manufacturers industry median Current Ratio is 2.00. Windlas Biotech's value of 1.95 is 2.5% below this industry median. Based on the distribution chart, Windlas Biotech ranks #509 out of 995 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #509 out of 995 companies for Current Ratio. This places Windlas Biotech in the lower half of its industry. The industry median Current Ratio is 2.00. Windlas Biotech's value of 1.95 is 2.5% below this benchmark. Historically, Windlas Biotech's own Current Ratio has ranged from 1.25 to 4.06 over the past decade. While the company's 10-year median is 2.10 vs. the industry median of 2.00, Windlas Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Current Ratio of 1.95 is 2.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Current Ratio is 1.95, which is near median its own 10-year median of 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.98, compared to a current price of ₹859.00 — trading 8.3% below its estimated fair value. The current Current Ratio is 1.95, which is near median its 10-year median of 2.10 and 2.5% below the Drug Manufacturers industry median of 2.00. Windlas Biotech's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Current Ratio is 1.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹859.00 is trading 8.3% below its estimated GF Value™ of ₹936.98.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Current Ratio: 1.95 (near median its 10-year median of 2.10)
GF Value™: ₹936.98 vs. price of ₹859.00 (8.3% below fair value)
Industry Position: 2.5% below the Drug Manufacturers median (#509 of 995)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
86GF Score
Get the complete analysis for NSE:WINDLAS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
